

Appendix K. Tables 3 to 5 From Report Showing Data From PP Analysis of Vaccination Outcomes

Table 3. Demographic Characteristics of Participants with Vaccination Data Assessed

Participant Characteristics		Arm Assignment			All % (N)
		Usual Care % (n)	Tailored % (n)	Untailored % (n)	
Young Adults		41% (108)	32% (84)	40% (115)	38% (307)
Parents		59% (158)	68% (175)	60% (165)	62% (498)
TOTAL (100% column)		266	259	280	100% (805)
Gender					
Young Adults	Male	0% (0)	0% (0)	0% (0)	0% (0)
	Female	100% (108)	100% (84)	100% (115)	100% (307)
	Missing	0	0	0	0
	TOTAL	108	84	115	100% (307)
Parents (Adolescent Gender)	Male	56% (88)	53% (92)	49% (81)	52% (261)
	Female	44% (70)	47% (83)	51% (84)	48% (237)
	Missing	0	0	0	0
	TOTAL	158	175	165	100% (498)
Race					
Young Adults	White	20% (22)	19% (16)	31% (36)	24% (74)
	African American	<1% (1)	0% (0)	0% (0)	<1% (1)
	Asian	0% (0)	0% (0)	<1% (1)	<1% (1)
	American Indian	2% (2)	<1% (1)	1% (2)	2% (5)
	Other	76% (82)	80% (67)	66% (76)	73% (225)
	Missing/Unknown	<1% (1)	0% (0)	0% (0)	<1% (1)
TOTAL	108	84	115	100% (307)	
Parents (Adolescent Race)	White	25% (39)	22% (38)	21% (34)	22% (111)
	African American	0% (0)	0% (0)	0% (0)	0% (0)
	Asian	0% (0)	<1% (1)	0% (0)	<1% (1)
	American Indian	<1% (1)	3% (5)	2% (3)	2% (9)
	Other	74% (117)	75% (130)	78% (128)	75% (375)
	Missing/Unknown	<1% (1)	<1% (1)	0% (0)	<1% (2)
	TOTAL	158	174	165	100% (498)
Ethnicity					
Young Adults	Hispanic	89% (96)	89% (75)	90% (104)	90% (275)
	Non-Hispanic	10% (11)	9% (8)	10% (11)	10% (30)
	Missing	1% (1)	1% (1)	0% (0)	<1% (2)
	TOTAL	108	84	115	100% (307)
Parents (Adolescent Ethnicity)	Hispanic	90% (142)	91% (158)	90% (148)	90% (449)
	Non-Hispanic	10% (16)	9% (16)	10% (17)	10% (49)
	Missing	0% (0)	0% (0)	0% (0)	0% (0)
	TOTAL	158	174	165	100% (498)
Age at Baseline		Median Age (MED)			Average
Young Adults		23	22	24	23
Parents (Adolescent Age)		12	12	11	11

Table 4. HPV Vaccine Uptake in Young Adults and Adolescents Across the 3 Study Arms

Participant Population	Arm Assignment						p-value ^a
	Usual Care		Tailored		Untailored		
	# eligible for outcome assessed	% of eligible vaccinated (n)	# eligible for outcome assessed	% of eligible vaccinated (n)	# eligible for outcome assessed	% of eligible vaccinated (n)	
Young Adults							
Got Any Dose of HPV During Study	108	3% (3)	84	6% (5)	115	6% (7)	0.45
Initiated the Vaccine Series ^b	85	4% (3)	66	8% (5)	93	3% (3)	0.43
Initiated the Vaccine, Series not Completed ^c	3	33% (1)	5	80% (4)	3	100% (3)	0.36
Completed the Vaccine Series, Among All Eligible ^d	99	2% (2)	79	1% (1)	102	4% (4)	0.63
Completed the Vaccine Series Among Those Initiated at Study Start ^e	23	0% (0)	18	0% (0)	22	18% (4)	0.02
Completed the Vaccine Series, Among Those Who Initiated During the Study ^f	3	67% (2)	5	20% (1)	3	0% (0)	0.36
Adolescents							
Got Any Dose of HPV During Study	158	47% (74)	175	49% (81)	165	53% (88)	0.49
Initiated the Vaccine Series ^b	93	34% (32)	115	42% (48)	95	46% (44)	0.25
Initiated the Vaccine, Series not Completed ^c	30	77% (22)	42	79% (33)	41	89% (36)	0.41
Completed the Vaccine Series, Among All Eligible ^d	140	21% (29)	158	23% (37)	151	18% (27)	0.49
Completed the Vaccine Series Among Those Initiated at Study Start ^e	65	42% (27)	60	53% (32)	70	33% (23)	0.06
Completed the Vaccine Series, Among Those Who Initiated During the Study ^f	30	23% (7)	42	21% (9)	41	12% (5)	0.41

^a P-value for three arm comparison of % vaccinated

^b Describes those who had 0 doses at study enrollment and received at least one dose during the study period. ^c Describes those who enrolled in the study with 0 doses, had enough time in the study period after the most recent dose to complete the series, but did not complete the series during the study period.

^dDescribes those who enrolled in the study with 0, 1 or 2 doses, had enough time in the study period after the most recent dose to complete the series, and completed the series during the study period.

^eDescribes those who enrolled in the study with 1 or 2 doses, had enough time in the study period after the most recent dose to complete the series, and completed the series during the study period.

^fDescribes those who enrolled in the study with 0 doses, had enough time in the study period after the most recent dose to complete the series, and completed the series during the study period.

Bolded p-values highlight significant or near significant results.

Table 5. Two Way Comparisons of Adolescent Vaccination Between Study Arms

Table 10. Two Way Comparisons of Adolescent Vaccination Between Study Arms			
Outcome	Comparison Arms	Difference, 95% CI	P-value ^a
Got Any Dose of HPV During Study	Tailored vs. Usual Care	2.3 (-8.4, 13.0)	0.674
	Untailored vs. Usual Care	6.5 (-4.4, 17.4)	0.242
	Untailored vs. Tailored	4.2 (-6.4, 14.8)	0.439
Initiated the Vaccine Series ^b	Tailored vs. Usual Care	7.3 (-5.9, 20.5)	0.277
	Untailored vs. Usual Care	11.9 (-2.0, 25.8)	0.094
	Untailored vs. Tailored	4.6 (-8.9, 18.1)	0.506
Initiated the Vaccine, Series not Completed ^c	Tailored vs. Usual Care	1.9 (-17.7, 21.5)	0.849
	Untailored vs. Usual Care	11.1 (-7.0, 29.3)	0.229
	Untailored vs. Tailored	9.2 (-6.7, 25.2)	0.256
Completed the Vaccine Series, Among All Eligible ^d	Tailored vs. Usual Care	2.7 (-6.7, 12.1)	0.574
	Untailored vs. Usual Care	-2.8 (-11.9, 6.2)	0.541
	Untailored vs. Tailored	-5.5 (-14.5, 3.5)	0.228
Completed the Vaccine Series Among Those Already Initiated at Study Start ^e	Tailored vs. Usual Care	11.8 (-5.6, 29.2)	0.184
	Untailored vs. Usual Care	-8.7 (-24.9, 7.6)	0.296
	Untailored vs. Tailored	-20.5 (-37.2, -3.7)	0.017
Completed the Vaccine Series, Among Those Who Initiated During the Study ^f	Tailored vs. Usual Care	-1.9 (-21.5, 17.7)	0.849
	Untailored vs. Usual Care	-11.1 (-29.3, 7.0)	0.229
	Untailored vs. Tailored	-9.2 (-25.2, 6.7)	0.256

^a P-value for the % vaccinated among the two arms denoted

^bDescribes those who had 0 doses at study enrollment and received at least one dose during the study period. ^cDescribes those who enrolled in the study with 0 doses, had enough time in the study period after the most recent dose to complete the series, but did not complete the series during the study period.

^dDescribes those who enrolled in the study with 0, 1 or 2 doses, had enough time in the study period after the most recent dose to complete the series, and completed the series during the study period.

^eDescribes those who enrolled in the study with 1 or 2 doses, had enough time in the study period after the most recent dose to complete the series, and completed the series during the study period.

^fDescribes those who enrolled in the study with 0 doses, had enough time in the study period after the most recent dose to complete the series, and completed the series during the study period.

Bolded p-values highlight significant or near significant results.